Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization
Luca Mastracci(Ospedale Policlinico San Martino), Maria Pia Pistillo(Ospedale Policlinico San Martino), Marina Gualco, Béatrice Dozin(Ospedale Policlinico San Martino), Alessandro Poggi(Ospedale Policlinico San Martino), Anna Morabito(Ospedale Policlinico San Martino), Francesco Spagnolo(Martin University), Barbara Banelli(Ospedale Policlinico San Martino), Paola Queirolo, Roberta Carosio(Ospedale Policlinico San Martino), Andrea Boutros(The University of Sydney), Massimo Romani(Ospedale Policlinico San Martino), Vincenzo Fontana(Ospedale Policlinico San Martino), Federica Grillo(Ospedale Policlinico San Martino), Sandra Salvi(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino)
Cited by 25
Related Papers
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
|International Journal of Cancer|2005|322